Christine E. Swenson

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2011 · 300 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Gerald Batist, Karen A. Gelmon, Kim N. et al. · Clinical Cancer Research · 2009 · 211 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

K. Mross, Bernward Niemann, Ulrich Massing et al. · Cancer Chemotherapy and Pharmacology · 2004 · 135 citations

Medicine, Pharmacokinetics, Pharmacology +11

Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)

Christine E. Swenson, Walter R. Perkins, Patricia J. Roberts et al. · The Breast · 2001 · 132 citations

Pharmacy, Biotechnology, Pharmaceutical Biotechnology +10

Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities

A S Janoff, Walter R. Perkins, Stephen Saletan et al. · Journal of Liposome Research · 1993 · 122 citations

Life Sciences, Biochemistry, Pharmacology +17